Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Immutep Plans Presentation of Final Survival Data From Head and Neck Cancer Trial in December

By Public Technologies
  • Immutep will present survival data from two trials of eftilagimod alfa in combination with Keytruda at international congresses in November and December 2026.
  • EFTISARC-NEO Phase II survival results will be presented at CTOS on Nov. 19, covering treatment with radiotherapy before surgery for resectable soft-tissue sarcoma.
  • TACTI-003 Part B final overall survival results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.
  • The latter trial evaluates first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma in patients with PD-L1-negative tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.